Neurologist and author Daniel Gibbs, PhD, joins the podcast to discuss his recent book, “A Tattoo on My Brain,” which details his journey from treating Alzheimer’s disease clinically for 25 years to being diagnosed with early-stage Alzheimer’s. Dr. Gibbs discusses early signs he experienced and daily life with the disease, as well as thoughts on the recent FDA-approved treatment aducanumab (marketed as Aduhelm).
Guest: Daniel Gibbs, PhD, neurologist
Episode TopicsWhat inspired the title of your book, “A Tattoo on the Brain”? 1:01
What were these early signs of Alzheimer's disease that you recognized in yourself? 3:42
What were your impressions of the clinic process, and where is there room for improvement? 8:08
Can you share your view on family history? 9:17
What do you say to people about direct-to-consumer genetic testing, both as a recipient and as a clinician? 10:57
Did knowing your risk of Alzheimer's disease help or harm you? 12:42
Did you find any habit difficult to incorporate into your day? 13:17
How important was it for you to be involved in research and what did you gain from being a research participant? 17:15
How do you feel about the recent FDA approval of aducanumab for clinical use? 20:25
As a patient, would you sign up for this drug, and if you were still working as a neurologist, would you prescribe this drug? 22:59
How do you find the balance between enjoying daily life and engaging proactive activities meant to improve the future? 24:49
How can we reframe the way people understand Alzheimer's disease? 28:18
Was it difficult to publicly discuss your experience, and what have you learned from this process? 29:52
What do you hope the reader takes away from your book? 31:15
Find Dementia Matters online
Follow us on Facebook
Follow us on Twitter
Bioenergetics: How Mitochondria Affects Alzheimer’s Disease and Aging
Looking Toward the Future: How Preclinical Alzheimer’s Disease Biomarker Disclosures Impact Society
Mixed Dementia, Explained
The Case for Disclosing Biomarker Results to Alzheimer’s Research Participants
Promoting Open Science and Community Engagement with the National Institute on Aging
Moving into the Digital Era of Alzheimer’s Disease Research
National Efforts to Standardize Brain Scan Data for More Accurate Alzheimer’s Risk Predictions
Protecting Participant Privacy and Making Predictions Using Alzheimer’s Data
The Future of Sharing and Accessing Alzheimer’s Disease Data
Introducing the National Alzheimer’s Coordinating Center
Study Shows APOE e4 Not Associated with Alzheimer’s Disease in American Indian Populations
Improving Registries and Representation in Alzheimer’s Disease Research
Highlights from the 2022 Alzheimer’s Association International Conference
COVID-19 and Its Effects on the Brain
Apathy and Alzheimer’s Disease: Plenary Preview with Dr. Krista Lanctôt
Scientific Importance of Diversity in Alzheimer’s Disease Research
Delirium and Dementia: Plenary Preview with Dr. Sharon Inouye
Non-Pharmacological Care for People with MCI and Dementia: Plenary Preview with Dr. Linda Lam
Opening Doors to Research Participants: Making Scientific Conferences Accessible to the Public
The World’s Largest Forum for Alzheimer’s Research: Introducing the AAIC 2022 Special Series
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Life in the A-Zone
Caregiver Storyteller - About Alzheimer’s and Dementia Caregiving
The Life, Love, and Alzheimer’s Podcast
Fading Memories: Alzheimer’s/Dementia Caregiver Support
Alzheimer’s Speaks